Showing results (341-350 of 415) with videos related to

Sort By:
Pageof 42
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
British Journal of Haematology|May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasAmer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemiasJudith E Karp, Antonino Passaniti, Ivana Gojo, et al.
Blood|January 21, 2012
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemiaJonathan M Gerber, B Douglas Smith, Brownhilda Ngwang, et al.
Blood|March 24, 2005
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabineRuben A Mesa, David Loegering, Heather L Powell, et al.
The Journal of Biological Chemistry|November 6, 2009
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergyXue Wei Meng, Michael P Heldebrant, Karen S Flatten, et al.
Leukemia Research|September 29, 2017
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemiaJonathan A Webster, Raoul Tibes, Larry Morris, et al.
Leukemia|December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeJorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 MutationsDaniel A Pollyea, Courtney D DiNardo, Martha L Arellano, et al.
Leukemia Research|December 8, 2009
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Amanda Blackford, B Douglas Smith, et al.
Pageof 42